🚨 "Free healthcare" in Canada? Think again. Most Canadians believe OHIP and provincial health plans cover everything if they get sick. But the reality is that nearly 2 in 5 Canadians will face a cancer diagnosis in their lifetime—and provincial healthcare doesn't cover: ❌ Outpatient prescription medications and breakthrough therapies. ❌ Travel costs to specialized treatment centers. ❌ Your mortgage, car payments, and bills when you take time off work. ❌ Lost income when your spouse takes leave to become your full-time caregiver. Without a plan, families are forced to drain their TFSAs, raid RRSPs, or rack up high-interest debt just to get through treatment. That's why proactive Canadians use Critical Illness Insurance: 💰 An immediate, tax-free lump-sum payout ($100k - $250k+) directly to you upon diagnosis. 🏥 Complete freedom to seek second opinions, access experimental treatments, or pay off debt. 🔄 Return of Premium (ROP): If you stay healthy and never make a claim, you can get 100% of your money back! 👉 Have you ever checked how much your workplace benefits cover for major illnesses? Drop your thoughts below! #CriticalIllness #HealthInsuranceCanada #LivingBenefits #PersonalFinanceCanada #CancerAwareness #FinancialPlanningCanada #LifeInsuranceCanada #WealthProtection #CanadianHealthcare #DisabilityInsuranceread more
One of my stocks that I funded completely by money I diverted from skipping coffee, had had a helluva week. Helluva month too... Isn't it nice, on these red days, when you see a little glimmer of hope within? 😅
These past few days have been quite a ride for Biotechnology. Lead pulmonary treatment company United Therapeutics (UTHR) has been fighting a vigorous patent war against competing company Liquidia (LQDA), with UTHR filing lawsuits over the use of various patents against Liquidia since 2020. The District Judge of Delaware last night ruled in favor of UTHR, and they are actively pushing for the FDA to block Liquidia's flagship product, Yutrepia, from entering the market for the treatment of PH-ILD. Could this re-instate United Therapeutics as the lead player in pulmonary treatment? How badly will this affect Liquidia in the long run? *FYI I am not a liscensed financial analyst I just study the medical stock sector for fun :)*
With questions surrounding the benefits of AI, Nano chips, quantum computing and many other technologies, it seems like we are almsot forgetting the other sides of the Tech landscape. Deeper beneath the surface we have machine vision, edge computing, machine learning and many more. BUT... At the deepest end of Tech world, we have perhaps the most scientifically fascinating sector... Medical Implants and Bio-Implantable Technology The technology responsible for incorporating ai into the human body itself, as well as doing the necessary work to monitor the patients outside the hospital, ensuring they are healthy, active and arent at risk of organ failure. Stocks with fascinating Tech: Neuropace / NPCE NovoCure / NVCR Inspire Medical / INSP Nyxoah SA / NYXH electroCORE inc. / ECOR *FYI I am not a medical sector analyst, all the info I gather is from my own personal research and fascination with the med-tech sector.* read more
Wall Street is quietly getting MUCH more bullish on $OSCR Over the last 30 days: 2026 EPS estimates: +18.8% 2027 EPS estimates: +24% That’s a pretty massive revision in just one month. The market is finally starting to catch up to what Oscar laid out at Investor Day.read more
I’ve seen a lot of mentions about this stock over the last couple months. Thought I missed a good opportunity but the other day, I thought why not just put a little in and see what happens. It’s jumped over 30% today. Outlooks have been raised and if you do a little research, you can see why Congrats to everyone who bought a couple months ago, that return has to be looking really nice!
Senior Portfolio Manager Martin Cobb warned on BNN Bloomberg that rising U.S. 🇺🇸 national debt ($10T maturing soon plus a $2T annual deficit) and weakening demand for U.S. 🇺🇸 Treasuries pose a major threat to markets via rising bond yields. Because higher yields can squeeze stock valuations, Cobb recommends deploying cash into high-quality, durable healthcare companies with strong cash flows and low sensitivity to debt markets. Here is how CAD and USD investors can position for this market environment: For US 🇺🇸 Dollar Investors (USD) * Direct Stock Picks: Zoetis ($ZTS) for animal health, EssilorLuxottica ($ESLOY) for global optics and wearable tech, and Smith & Nephew ($SNN) for medical devices. * Healthcare & Defensive ETFs: Vanguard Health Care ETF ($VHT) or Health Care Select Sector SPDR Fund ($XLV) for broad sector defense against market shifts. For Canadian 🇨🇦 Dollar Investors (CAD) * Direct Stock Access: Invest directly in Cobb's picks ($ZTS, $SNN, $ESLOY) via USD accounts or CDR equivalents where available. * Healthcare & Defensive ETFs: Harvest Healthcare Leaders Income ETF ($HHL) or iShares Global Healthcare Index ETF ($XHC) to gain Canadian dollar-denominated exposure to resilient global healthcare leaders. Did You Know? 🧐 The U.S. government now spends nearly 20% of all tax revenues just paying interest on its debt! That massive fiscal strain is why seasoned investors like Martin Cobb look for cash-generative healthcare companies that don't rely on borrowing to fund growth. — This post is for educational and informational purposes only and does not constitute financial or investment advice.read more
What are people's thoughts on $ABCL? Was doing good for a few months, now down nearly 6% this week. New menopause drug is almost in final phase. Is this a good time to buy more?
Some talk has picked up on the worry of how to handle the large number of elderly people that the world is going to have. This rise is starting as soon as 2030. I don’t think it’s a financial market that can really fail because the demand for it is going to be hard to meet with how much will be required. I have chosen to invest in $AGNG because it has a large focus on the biotech behind supporting an ageing population. It also has worldwide exposure, which is nice. The second stock I have chosen to invest in is $WELL because of its dominance in the health care real estate market. It has exposure centrally in the USA, but also throughout all of North America and the UK. We are already seeing its demand now with waitlists for long term care where people don’t get in before they die. The infrastructure behind the Silver Tsunami is a huge opportunity.
Thank you Blossom for now supporting Australian brokerages and Australian stocks. I have been MIA from the platform, serious life stuff. But I'm glad I can now actually use the platform to showcase my investments. Shoutout Cogstate, ASX: CGS for your fantastic growth. Somewhat disappointed though I didnt load up on more of it in advance before other people discovering this stock.
I’ve been looking at $XLV going into the midterms, and what interests me most is the uncertainty around the setup. Historically, buying XLV around the end of September in midterm years and holding through the end of November has worked pretty well 2002: +9.1% 2006: +0.2% 2010: -0.8% 2014: +9.0% 2018: +0.8% 2022: +14.8% That’s 5 out of 6 positive periods, with an average return of about +5.5%. What makes the setup interesting to me is that healthcare tends to be a defensive area when there’s a lot of uncertainty, and midterms usually bring plenty of that. You also have questions around regulation, Medicare, drug pricing and healthcare policy hanging over the sector. Once the election is over, some of that uncertainty gets removed, and historically the broader market has often responded well after midterms. So my thinking is pretty simple, uncertainty now could create the setup, and more clarity after the election could be the catalyst. The sample size is obviously small, so I’m not treating the 83% hit rate like a guarantee. I just think it’s an interesting historical pattern to have in mind given where we are right now. read more
I believe AI will be a game changer for the vast majority of sectors. We put big focus on 📈semiconductors💻, 🧍humanoid robots🦾, 🤖agents🤖, 📊Cybersecurity👨💻 and more… HOWEVER, with the sheer amount of logistics, diverse sectors, workflows, technologies and hardware in the medical sector, PERHAPS AI will be less about automating surgeries, and more about accelerating the long, repetitive, physically and mentally demanding tasks that that doctors and scientists hate. Perhaps we might be undervaluing the sheer potential AI has on the human body itself. I’m curious to see what everyone else thinks about this… read more
